Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy

Inclusion Criteria: * Men or women 18 to 70 years of age, inclusive * Body mass index of 27 to 45 kg/m2 * Diagnosed with T2DM for at least 6 months before screening * Stable daily dose of metformin monotherapy of ≥1000 mg for at least 3 months before screening * FPG ≤240 mg/dL at screening * HbA1c ≥7.0% and ≤11% at screening * A 12-lead electrocardiogram recording without clinically significant arrhythmia, left bundle-branch block, or corrected QT interval Exclusion Criteria: * Pregnant or breastfeeding women * Use of a weight control treatment, including over-the-counter medications (includes herbal supplements), or a significant change in body weight (at least ±10%) in the 3 months before screening * Treatment with any oral antidiabetic agent other than metformin within the 3 months before screening * Treatment with insulin for longer than 1 week within the 3 months before screening or any treatment with insulin within the 2 weeks before screening * Previous treatment with a glucagon-like peptide 1 (GLP-1) analog or other incretin therapy * Receipt of any experimental drug in a clinical trial within 30 days before administration of study drug or receipt of any investigational antidiabetic product within 3 months before screening